Processing and components: Leucodepletion and pathogen reduction

Transfusion Microbiology

Volumn , Issue , 2008, Pages 239-258

  Cardigan, Rebecca ^a   Prowse, Chris ^a   Williamson, Lorna M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 62349093765     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545245.023     Document Type: Chapter

References (151)

1. Alarcon, P. de, Benjam, R. J., Shopnick, R., et al. (2003) Patients with congenital coagulation factor deficiencies demonstrate consistent therapeutic responses to repeated transfusions of plasma prepared with pathogen inactivation treatment (INTERCEPT plasma). Blood, 102(11), 815a.
2. Allford, S. L., Harrison, P., Lawrie, A. S., et al. (2000) von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic pur-pura. Br J Haematol, 111, 1215-22.
3. Alvarez-Larran, A., Del Rio, J., Ramirez, C., et al., (2004) Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang, 86, 246-51.
4. Atance, R., Pereira, A. and Ramirez, B. (2001) Tranfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion, 41, 1548-52.
5. AuBuchon, J. P., Pickard, C. A., Herschel, L. H., et al. (2002) Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: A phase I clinical study. Transfusion, 42(2), 146-52.
6. Aytay, A., Ohagen, A., Busch, M., et al. (2003) Development of a sensitive long-range PCR system to demonstrate viral nucleic acid inactivation. Transfusion, 43(Suppl. 8A), S26-030E.
7. Aznar, J. A., Bonand, S., Montoro, J. M., et al. (2000) Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants. Vox Sang, 79, 56-160.
8. Aznar, J. A., Molina, R. and Montoro, J. M. (1999) Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion, 39, 748-50.
9. Bachmann, B., Knuver-Hopf, J., Lambrecht, B., et al. (1995) Target structures for HIV-1 inactivation by methylene blue and light. J Med Virol, 47(2), 172-8.
10. Beck, K. H., Mortelsmans, Y., Kretschmer, V. V., et al. (2000) Comparison of solvent/detergent-inactivated plasma and fresh frozen plasma under routine clinical conditions. Infusionstherapie und Transfusionsmedizin, 27, 144-8.
11. Beeck, H. and Hellstern, P. (1998) In vitro characterisation of solvent/detergent-treated human plasma and of quarantine fresh-frozen plasma. Vox Sang, 74(Suppl. 1), 219-23.
12. Bowden, R. A., Slichter, S. J., Sayers, M., et al. (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood pro-ducts for the prevention of transfusion-associated CMV infection after marrow transplant. Blood, 86, 3598-603.
13. Brown, P., Cervenakova, L., McShane, L. M., et al. (1999) Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion. 39, 1169-78.
14. Brown, P., Rohwer, R. G., Dunstan, B. C., et al. (1998) The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion, 38(9), 810-6.
15. Cardigan, R., Allford, S. and Williamson, L. M. (2002) Levels of von Willebrand factor cleaving protease are normal in methylene blue treated fresh frozen plasma. Br J Haematol, 117, 253-4.
16. Cervenakova, L., Yakovleva, O., McKenzie, C., et al. (2003) Similar levels of infec-tivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion, 43, 1687-94.
17. Chapman, J. R., Moore, K. and Butterworth, B. E. (2003a) Pathogen inactivation of RBCs: PEN110 reproductive toxicology studies. Transfusion, 43, 1386-93.
18. Chow, T. W., Turner, N. A., Chintagumpala, M., et al. (1998) Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol, 57(4), 292-302.
19. Ciaravino, V. (2001) Preclinical safety of a nucleic acid-targeted Helinx compound: A clinical perspective. Seminars in Hematology, Oct, 38(4) Suppl. 11, 12-19.
20. Ciaravino, V., McCullough, T. and Cimino, G. (2003a) The role of toxicology assessment in transfusion medicine. Transfusion, 43, 1481-92.
21. Ciaravino, V., McCullough, T., Cimino, G., et al. (2003b) Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sang, 85, 171-82.
22. Ciavarino, V., Sullivan, T. and McCullough, T. (2003c) The absence of repro-ductive toxicity demonstrated by the INTERCEPT blood system for plate-lets. Transfusion, 43(Suppl). 84A, SP-143.
23. Clark, B., Castro, G. and Stassinopoulos, A. (2003) Treatment with Helinx technology does not affect the ability of red blood cells to overcome oxida-tive stress. Transfusion, 43(Suppl), S30-030E.
24. Cook, D., Stassinopoulos, A., Merritt, J., et al. (1997) Inactivation of pathogens in packed red blood cell (PRBC) concentrates using S-303. Blood, 90(Suppl. 1), 409a.
25. Cook, D., Stassinopoulos, A., Wollowitz, S., et al. (1998) In vivo analysis of packed red blood cells treated with S-303 to inactivate pathogens. Blood, 92(Suppl. 1), 503a.
26. Corash, L. (2000) Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates. Vox Sang, 78(Suppl. 2), 205-10.
27. Corash, L. (2003) Pathogen reduction technology: Methods, status of clinical trials, and future prospects. Current Hematology Reports, 2, 495-502.
28. Corash, L. and Lin, L. (2004) Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplantation, 33, 1-7.
29. Corash, L., Behrman, B., Rheinschmidt, M., et al. (1997) Post-transfusion viabi-lity and tolerability of photochemically treated platelet concentrates (PC). Blood, 90(10), S1, 267a.
30. Corbin, F. (2002) Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photo-sensitizer. Internat J Hematol, 76(Suppl. 2), 253-7.
31. Council of Europe (2001) Council of Europe expert committee in blood trans-fusion study group on pathogen inactivation of labile blood components. Pathogen inactivation of labile blood products. Transfus Med, 11(3), 149-75.
32. Council of Europe (2007) Council of Europe Guide to the Preparation, Use and Quality Assurance of Blood Components. 13th edn, 2007, Strasbourg. Council of Europe Publishing.
33. De la Rubia, J., Arriaga, F., Linares, D., et al. (2001) Role of methylene blue treated or fresh frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol, 114, 721-3.
34. Doyle, S., O'Brien, P., Murphy, K., et al. (2003) Coagulation factor content of solvent detergent plasma compared with fresh frozen plasma. Blood Coag Fibrinolysis, 14, 283-7.
35. Dupuis, K. W. (2003c) West Nile virus is inactivated by the Helinx tech-nology in human platelet concentrates. Transfusion, 43(Suppl. 82A), SP-135.
36. Dupuis, K. W. and Alfonso, R. (2003a) Helinx technology inactivates Trypanosoma cruzi in human red blood cells. Transfusion, 43(Suppl. 83A), SP-139.
37. Dupuis, K. W. and Alfonso, R. (2003b) Helinx technology inactivates intra-erythrocytic Plasmodium falciparum in human red blood cells. Transfusion, 43(Suppl. 83A), SP-140.
38. Edrich, R., Benford, L., Urioste, M., et al. (2003) Bacterial decontamination of apheresis platelets using a photochemical treatment process with ribofla-vin. Transfusion, 43(Suppl. 79A), SP-125.
39. Epstein, J. S. and Vostal, J. G. (2003) FDA approach to evaluation of pathogen reduction technology. Transfusion, 43, 1347-50.
40. Evans, G., Llewelyn, C., Luddington, R., et al. (1999) Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocyto-penic purpura. Clin Lab Haematol, 21, 119-23.
41. Fast, L. D., DiLeone, G., Edson, C. M., et al. (2002a) PEN110 treatment function-ally inactivates the PBMNCs present in RBC units: Comparison to the effects of exposure to gamma irradiation. Transfusion, 42, 1318-25.
42. Fast, L. D., DiLeone, G., Edson, C. M., et al. (2002b) Inhibition of murine GVHD by PEN110 treatment. Transfusion, 42, 1326-32.
43. Fast, L. D., Semple, J. W., DiLeone, G., et al. (2004) Inhibition of xenogeneic GvHD by PEN 110 treatment of donor human PBMNCs. Transfusion, 44(2), 282-5.
44. Furlan, M., Robles, R., Galbusera, M., et al. (1998) Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemo-lytic-uremic syndrome. N Eng J Med, 339, 1578-84.
45. Garwood, M., Cardigan, R., Hornsey, V., et al. (2003) The effect of methylene blue photoinactivation and removal on the quality of fresh-frozen plasma (FFP). Transfusion, 43, 1238-47.
46. Gibb, A. P., Martin, K. M., Davidson, G. A., et al. (1994) Modelling the growth of Yersinia enterocolitica in donated blood. Transfusion, 34, 304-310.
47. Goltsina, H., Chapman, J. and Purmal, A. (2003) Chemical interaction of INACTINE PEN110 with nucleic acids. Transfusion, 43(Suppl. 85A), SP-145.
48. Goodrich, R. P. (2000) The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang, 78(Suppl. 2), 211-5.
49. Goodrich, R. P., Janssens, M., Ghielli, M., et al. (2003) Correlation of in vitro parameters and in vivo recovery and survival for PRT treated platelets in normal human donors. Transfusion, 43(Suppl. 79A), SP-126.
50. Grass, J. A., Hei, D. J., Metchette, K., et al. (1998) Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood, 91, 2180-8.
51. Greenwalt, T. J., Hambleton, J., Wages, D., et al. (1999) Viability of red blood cells treated with a novel pathogen inactivation system. Transfusion, 39, S497.
52. Gregori, L., McCombie, N., Palmer, D., et al. (2004) Effectiveness of leucoreduc-tion for removal of infectivity of transmissible spongiform encephalopa-thies from blood. Lancet, 364, 529-31.
53. Guidelines for the Blood Transfusion Services in the United Kingdom. 7th edn, 2005. London, Stationery Office.
54. Hambleton, J., Wages, D., Radu-Radulescu, L., et al. (2002) Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion, 42, 1302-7.
55. Harrison, C. N., Lawrie, A. S., Iqbal, A., et al. (1996) Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocyto-penic purpura. Br J Haematol, 94, 756-8.
56. Haubelt, H., Blome, M., Kiessling, A. H., et al. (2002) Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang, 82, 9-14.
57. Hei, D. J., Grass, J., Lin, L., Corash, L. and Cimino, C. (1999) Elimination of cytokine production in stored platelet concentrate aliquots by photoche-mical treatment with psoralen plus ultraviolet A light. Transfusion, 39, 239-48.
58. Heiden, M., Salge, U., Breitner-Ruddock, S., et al. (2003) Significant difference between S/D plasma qualities of different origin. Transfusion, 43(Suppl. 56A), SP-47.
59. Hellstern, P., Larbig, E., Walz, G. A., et al. (1993) Prospective study on efficacy and tolerability of solvent/detergent-treated plasma in intensive care unit patients. Infusther Transfusmed, 20 (Suppl. 2), 16-18.
60. Hellstern, P., Sachse, H., Schwinn, H., et al. (1992) Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang, 63, 178-85.
61. Hillyer, C. D., Roback, J. D., Saakadze, N., et al. (2003) Transfusion-transmitted cytomegalovirus (CMV) infection: Elucidation of role and dose of mono-cytes in a murine model. Blood, 102(11), 57a.
62. Hillyer, K. L., Kelly, V. A., Roush, K. S., et al. (2001) Von Willebrand factor-cleaving protease (VWF-CP) activity in S-59 treated donor plasma. Blood, 98(Suppl. 1), 539a.
63. Holada, K., Vostal, J. G., Theisen, P. W., et al. (2002) Scrapie infectivity in ham-ster blood is not associated with platelets. J Virol, 76, 4649-50.
64. Hornsey, V. S., Krailadsiri, P., MacDonald, S., et al. (2000) Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma. Br J Haematol, 109, 665-70.
65. Hornsey, V. S., Young, D. A., Docherty, A., et al. (2004) Cryoprecipitate prepared from plasma treated with methylene blue plus light: Increasing the fibrino-gen concentration. Transfus Med, 14, 369-74.
66. Horowitz, B., Bonomo, R., Prince, A. M., et al. (1992) Solvent/detergent-treated plasma: A virus-inactivated substitute for fresh frozen plasma. Blood, 79, 826-31.
67. Horowitz, M. S. and Pehta, J. C. (1998) SD plasma in TTP and coagulation factor deficiences for which no concentrates are available. Vox Sang, 74 (Suppl. 1), 231-5.
68. ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) (1998) downloadable files (available from: Www.ich.org) under guidelines/safety topics (see also Fed. Reg., 1997, 62, 62922).
69. Inada, Y., Hessel, B. and Blomback, B. (1978) Photo-oxidation of fibrinogen in the presence of methylene blue and its effect on polymerization. Biochim Biophys Acta, 25(532), 161-70.
70. Inbal, A., Epstein, O., Blickstein, D., et al. (1993) Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coag Fibrinolysis, 4, 599-604.
71. Jackson, B. R., AuBuchon, J. P. and Birkmeyer, J. D. (1999) Update of cost-effectiveness analysis for solvent-detergent treated plasma. J Am Med Assoc, 282, 329-30.
72. Keeling, D. M., Luddington, R., Allain, J.-P., et al. (1997) Cryoprecipitate pre-pared from plasma virally inactivated by the solvent detergent method. Br J Haematol, 96, 94-197.
73. Klein, H. G, Anderson, D., Bernardi, M. J., et al. (2007) Pathogen inactivation: Making decisions about new technologies-preliminary report of a con-sensus conference. Vox Sang, 93, 179-82.
74. Knutson, F., Alfonso, R., Dupuis, K., et al. (2000) Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under condi-tions that preserve in vitro platelet function. Vox Sang, 78, 209-16.
75. Krailadsiri, P., Seghatchian, J., Macgregor, I., et al. (2006). The effects of leuko-depletion on the generation and removal of microvesicles and prion pro-tien in blood components Transfusion, 46, 407-17.
76. Kumar, V., McLean, R., Keil, S., et al. (2003b) Mirasol pathogen reduction technology for blood products using riboflavin and UV illumination: Mode of action of riboflavin on pathogen nucleic acid chemistry. Transfusion, 43(Suppl. 79A), SP-124.
77. Kumar, V., Motheral, T., Luzniak, G., et al. (2003a) Mirasol plasma patho-gen reduction technology: riboflavin-based process conserves protein C, protein S and antithrombin activities. Transfusion, 43(Suppl. 80A), SP-128.
78. Lambrecht, B., Mohr, H., Knuver-Hopf, J., et al. (1991) Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang, 60, 207-13.
79. Laupacis, A., Brown, J., Costello, B., et al. (2001) Prevention of post-transfusion CMV in the era of universal WBC reduction: A consensus statement. Transfusion, 41, 560-69.
80. Lazo, A., Tassello, J., Jayarama, V., et al. (2002) Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry. Vox Sang, 83, 313-23.
81. Lazo, A., Tassello, J., Ohagen, A., et al. (2003) Inactivation of human parvovirus B19 by INACTINE PEN110. Transfusion, 43(Suppl. 86A), SP-147.
82. Leebeek, F. W. G., Schipperus, M. R. and van Vliet, H. H. D. M. (1999) Coagulation factor levels in solvent/detergent-treated plasma. Transfusion, 39, 1150-51.
83. Leiby, D. A. (2004) Threats to blood safety posed by emerging protozoan patho-gens. Vox Sang, 87 (Suppl. 2), 120-2.
84. Lerner, R. G., Nelson, J., Scorcia, E., et al. (2000) Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang, 79, 161-7.
85. Li, J., de Korte, D., Woolum, M. D., et al. (2004) Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: Comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang, 87, 82-90.
86. Lin, L., Cook, D. N., Wiesehahn, G. P., et al. (1997) Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion, 37, 423-35.
87. Llewelyn, C. A., Hewitt, P. E., Knight, R. S. G., et al. (2004) Possible transmission of variant Creutzfeld-Jacob disease by blood transfusion. Lancet, 363, 417-21.
88. Lopez-Plaza, I., Snyder, E., Goodnough, L. T., et al. for the SPRINT Study Group. (2003) INTERCEPT platelet transfusions are associated with fewer transfu-sion reactions than conventional platelet transfusions prepared by apher-esis with process leukoreduction. Transfusion, 43 (9S) 84A.
89. Lorenz, M., Muller, M., Jablonka, B., et al. (1998) High doses of methylene blue/light treatment crosslink the A-alpha-sub-unit of fibrinogen: Influence of this photo-oxidization on fibrinogen binding to platelets. Haemostasis, 28, 17-24.
90. Magner, J. J., Crowley, K. J. and Boylan, J. F. (2007) Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas). J Cardiothorac Vasc Anesth, 21, 410-3.
91. Mast, A. E., Stadanlick, J. E., Lockett, J. M., et al. (1999) Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood, 94, 3922-7.
92. Mather, T., Takeda, T., Tassello, J., et al. (2003) West Nile virus in blood: Stability, distribution and susceptibility to PEN110 inactivation. Transfusion, 43, 1029-37.
93. McCullough, J. (2003) Progress toward a pathogen-free blood supply. Clin Infect Dis, 37, 88-95.
94. McCullough, J., Vesole, D. H., Benjamin, R. J., et al. (2004) Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT trial. Blood, 104, 1534-41.
95. Mintz, P., Steadman, R., Blackall, D. et al. (2002) Pathogen inactivation of plasma using S-59 and UVA light is efficacious and well tolerated in the treatment of end-stage liver disease patients-the STEP AC trial. Transfusion, 42(Suppl), 15S.
96. Mintz, P. D., Neff, A., MacKenzie, M. et al. (2006) A randomized, controlled Pase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion, 46, 1693-704.
97. Moake, J., Chintagumpala, M., Turner, N., et al. (1994) Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood, 84, 490-7.
98. Mohr, H. and Redecker-Klein, A. (2003) Inactivation of pathogens in platelet concentrates by using a two-step procedure. Vox Sang, 84, 96-104.
99. Mohr, H., Bachmann, B., Klein-Struckmeier, A., et al. (1997) Virus inactivation of blood products by phenothiazine dyes and light. Photochem Photobiol Sci, 65, 441-5.
100. Mohr, H., Knuver-Hopf, J., Gravemann, U., et al. (2004) West Nile virus in plasma is highly sensitive to methylene blue/light treatment. Transfusion, 44, 886-90.
101. Mohr, H., Knuver-Hopf, J., Lambrecht, B., et al. (1992) No evidence for neoanti-gens in human plasma after photochemical virus inactivation. Ann of Hematol, 65, 224-8.
102. Murphy, S., Snyder, E., Cable, R., et al. (2003) Transfusion of INTERCEPT platelets vs. reference platelets at doses 2'.3 x 1011 results in comparable haemostasis and platelet and RBC transfusion requirements: Results of the SPRINT trial. Blood, 102(11), 815a.
103. Nichols, W. G., Price, T. H., Gooley, T., et al. (2003) Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood, 101, 4195-200.
104. Nifong, T. P., Light, J., Wenl, R. E. (2002) Coagulant stability and sterility of thawed solvent-detergent-treated plasma. Transfusion, 42, 1581-4.
105. O'Hagen, A., Gibaja, V., Aytay, S., et al. (2002) Inactivation of HIV in blood. Transfusion, 42, 1308-17.
106. Pamphilon, D. H., Rider, J. R., Barbara, J. A. J., et al. (1999) Prevention of transfusion-transmitted cytomegalovirus infection. Transfus Med, 9, 115-23.
107. Peden, A. H., Head, M. W., Ritchie, D. L., et al. (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet, 364, 527-9.
108. Peirera, A. (1999) Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion, 39, 479-87.
109. Pennington, J., Garner, S. F., Sutherland, J., et al. (2001) Residual subset popula-tion analysis in leucocyte depleted blood components using real-time quantitative RT-PCR. Transfusion, 41, 1591-600.
110. Pennington, J., Taylor, G. P., Sutherland, J., et al. (2002) Persistence of HTLV in blood donations after leucocyte depletion. Blood, 100, 677-81.
111. Pinkoski, L., Amir, S., Smyers, J., et al. (2001a) Photochemically treated plasma retains protein C, protein S and antithrombin activities. Transfusion Clinique et Biologique, 8(Suppl. 1), 101.
112. Pinkoski, L., Corash, L., Ramies, D., et al. (2002a) The INTERCEPT Plasma System: Helinx pathogen inactivation technology does not activate thrombin, complement, or the contact system of coagulation. Vox Sang, 83(Suppl. 2), 574.
113. Pinkoski, L., Ramies, D., Wiesehahn, G., et al. (2002b) The INTERCEPT blood system for plasma conserves key proteins necessary for effective transfu-sion support of hemostasis. Transfusion, 42(Suppl), 575.
114. Pinkoski, L., Smyers, J., Corash, L., et al. (2001b) Pathogen inactivation of plasma using Helinx technology conserves the activity of coagulation, anticoagulation and fibrinolytic proteins. Blood, 98, 541a.
115. Piquet, Y., Janvier, G., Selosse, P., et al. (1992) Virus inactivation of fresh frozen plasma by a solvent detergent procedure: Biological results. Vox Sang, 63, 251-6.
116. Pohl, U., Becker, M., Papstein, C., et al. (1995b) Methylene blue virus inactivated plasma in the treatment of patients with thrombotic thrombocytopenic purpura. ISBT 5th Regional (European) Congress, Venice.
117. Pohl, U., Wieding, J. U., Kirchmaier C. M., et al. (1995a) Treatment of patients with severe congenital coagulation factor V or XI deficiency with methylene blue virus inactivated plasma. ISBT 5th Regional (European) Congress, Venice.
118. Politis, C., Kavallierou, L., Hantziara, S., et al. (2007) Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years’ experience. Vox Sang, 92, 319-26.
119. Prowse, C. V., Hornsey, V. S., Drummond, O., et al. (1999) Preliminary assess-ment of whole-blood, red-cell and platelet-leucodepleting filters for possi-ble induction of prion release by leucocyte fragmentation during room temperature processing. Br J Haematol, 106, 240-7.
120. Prowse, C. V. and MacGregor, I. R. (2002) Mad cows and Englishmen: An update on blood and vCJD. Vox Sang, 83(Suppl. 1), 341-9.
121. Purmal, A., Valeri, C. R., Dzik, W., et al. (2002) Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: Pre-clinical studies. Transfusion, 42, 139-45.
122. Reidler, G. F., Haycox, A. R., Duggan, A. K., et al. (2003) Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang, 85, 88-95.
123. Rentas, F. J., Lippert, L., Harman, R., et al. (2003) Inactivation of Orientia tsut-sugamuchi (scrub typhus) in an animal model using the INTERCEPT blood system for human platelets. Transfusion, 43(Suppl. 84A), SP-141.
124. Rhenen, D. van, Gulliksson, H., Cazenave, J. P., et al. and EuroSPRITE trial (2003) Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial. Blood, 101, 2426-33.
125. Rhenen, D. J. van, Vermeij, J., Mayaudon, V., et al. (2000) Functional character-istics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang, 79(4), 206-14.
126. Rider, J. R., Want, E. J., Winter, M. A., et al. (2000) Differential leucocyte subpopula-tion analysis of leucodepleted red cell products. Transfus Med, 10, 49-58.
127. Ronghe, M. D., Foot, A. B. M., Cornish, J. M., et al. (2002) The impact of transfu-sion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation. Br J Haematol, 118, 1124-7.
128. Ruane, P. H., Edrich, R., Gampp, D., et al. (2004) Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion, 44, 877-85.
129. Simonsen, A. C. and Sorensen, H. (1999) Clinical tolerance of methylene blue virus-inactivated plasma: A randomized crossover trial in 12 healthy human volunteers. Vox Sang, 77, 210-7.
130. Sivakumaran, M., Hutchinson, R. M., Wood, J. K., et al. (1993) Removal of cyto-megalovirus (CMV) infected leucocytes from CMV positive blood units by bedside blood filtration. Br J Haematol, 85, 232-4.
131. Snyder, E., Mintz, P., Burks, S. et al. (2001) Pathogen inactivated red blood cells using INACTINE technology demonstrate 24 hour post-transfusion recovery equal to untreated red cells after 42 days of storage. Blood, 98, 709a.
132. Solheim, B., Tollofsrud, S., Noddeland, H., et al. (2002) Universal solvent/deter-gent treated plasma. Vox Sanguinis, 83, 111.
133. Solheim, B. G. and Hellstern, P. (2003) Composition and efficacy and safety of solvent-detergent treated plasma. Transfusion, 43, 1176-8.
134. Solheim B. G., Svennevig, J. L., Mohr, B., et al. (1993) The use of Octaplas in patients undergoing open heart surgery. In DIC: Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation, ed. G. Muller-Berghaus, pp. 253-62. Amsterdam, Elsevier.
135. Solheim, B. G., Cid, J. and Osselaer, J. C. (2006) Pathogen Reduction Technologies. Global Perspectives in Transfusion Medicine (ed. by M. Lozano, M. Contreras, &M. A. Blajchman), pp. 103-148. AABB Press, Bethesda.
136. Suontataka, A. M., Blomback, M. and Chapman, J. (2003) Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light. Transfusion, 43(5), 568-575.
137. Taborski, U., Oprean, N., Tessmann, R., et al. (2000) Methylene blue/light-treated plasma and the disturbance of fibrin polymerization in vitro and in vivo: A randomized, double-blind clinical trial. Vox Sang, 78, 546.
138. Van Voorhuis, W. C., Barrett, L. K., Eastman, R. T., et al. (2003) Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents and Chemother, 47, 475-9.
139. Visconti, M. R., Pennington, J., Garner, S. F., et al. (2003) Assessment of removal of human cytomegalovirus from blood components by leucocyte depletion filters using real-time quantitative PCR. Blood, 103, 1137-9.
140. Wadhwa, M., Seghatchian, M. J., Dilger, P., et al. (2000) Cytokine accumulation in stored red cell concentrates: Effect of buffy coat removal and leucore-duction. Transfus Sci, 23(1), 7-16.
141. Wages, D., Eden, P., Smyders, J., et al. (2000) Preparation of cryoprecipitate from photochemically treated fresh frozen plasma. Transfusion, 40 (Suppl), 63S. Wieding, J. U., Rathgeber, J., Zenker, D., et al. (1999) Prospective randomized and controlled study on solvent/detergent versus methylene blue/light virus-inactivated plasma. Transfusion, 39 (Suppl), 23S.
142. Williamson, L. M. (2000) Leucocyte depletion of the blood supply-how will patients benefit? Br J Haematol, 110, 256-72.
143. Williamson, L. M., Llewelyn, C. A., Fisher, N. C., et al. (1999) A randomised trial of solvent/detergent and standard fresh frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion, 39, 1227-34.
144. Wollowitz, S. (2001) Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol, 38(Suppl. 11), 4-11.
145. Yarranton, H., Cohen, H., Pavord, S. R., et al. (2003a) Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol, 121, 778-85.
146. Yarranton, H., Lawrie, A., Mackie, I., et al. (2003b) Coagulation factor levels in cryosupernatant treated with amotosalen hydrochloride (S-59) and UVA light-A suitable plasma replacement in thrombotic thrombocytopenic purpura. Blood, 102(11), 817a.
147. Yazer, M. H., Podlosky, L., Clarke, G., et al. (2004) The effect of prestorage WBC reduction on the rates of febrile non-hemolytic transfusion reactions to platelet concentrates and RBC. Transfusion, 44, 10-5.
148. Zavizion, B., Purmal, A. and Chapman, J. (2003b) Inactivation of Mycoplasma species in blood by INACTINE PEN110. Transfusion, 43(Suppl. 86A), SP-149.
149. Zavizion, B., Purmal, A., Serebryanik, D., et al. (2003c) Inactivation of anaerobic bacteria in red cell concentrates using INACTINE process. Transfusion, 43(Suppl. 86A), SP-148.
150. Zavizion, B., Serebryanik, D., Serebryanik, I., et al. (2003a) Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process. Transfusion, 43, 135-42.
151. Zeiler, T., Riess, H., Wittmann, G., et al. (1994) The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. Transfusion, 34, 685-9.